LONDON--(BUSINESS WIRE)--Speaking at the American Association for Clinical Chemistry (AACC) 2008 Conference and Exhibition in Washington, DC, James White, Chief Executive, Osmetech plc (LSE:OMH), confirmed that following receipt of its 510(k) clearance last week from the US Food & Drug Administration (‘FDA’), the Company has now commenced shipments of its second generation eSensor® XT-8 molecular diagnostics platform and Warfarin Sensitivity Test.
